U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H29NO3
Molecular Weight 307.4284
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOBETAXOLOL

SMILES

CC(C)NC[C@@]([H])(COc1ccc(cc1)CCOCC2CC2)O

InChI

InChIKey=NWIUTZDMDHAVTP-KRWDZBQOSA-N
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H29NO3
Molecular Weight 307.4284
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021114s003lbl.pdf

BETAXON™ is a trade name for levobetaxolol hydrochloride ophthalmic suspension 0.5%, which is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. The brand name Betaxon is discontinued in USA, but generic versions may be available. Levobetaxolol is a cardioselective (beta-1¬ adrenergic) receptor-blocking agent that does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Animal studies suggest levobetaxolol (S-isomer) is the more active enantiomer of betaxolol (racemate).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BETAXON

Approved Use

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Launch Date

9.5126402E11
Primary
BETAXON

Approved Use

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Launch Date

9.5126402E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.7 ng/g
1 drop 2 times / day multiple, ocular
dose: 1 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
LEVOBETAXOLOL plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.5 ng/mL
1 drop 2 times / day steady-state, ocular
dose: 1 drop
route of administration: Ocular
experiment type: STEADY-STATE
co-administered:
LEVOBETAXOLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.4 ng × h/g
1 drop 2 times / day multiple, ocular
dose: 1 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
LEVOBETAXOLOL plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
1 drop 2 times / day multiple, ocular
dose: 1 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
LEVOBETAXOLOL plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
1 drop 2 times / day steady-state, ocular
dose: 1 drop
route of administration: Ocular
experiment type: STEADY-STATE
co-administered:
LEVOBETAXOLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
48%
1 drop 2 times / day multiple, ocular
dose: 1 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
LEVOBETAXOLOL plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day steady, ophthalmic
Recommended
Dose: 0.5 %, 2 times / day
Route: ophthalmic
Route: steady
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, 1 - 6 years
n = 48
Health Status: unhealthy
Condition: pediatric glaucomas
Age Group: 1 - 6 years
Sex: M+F
Population Size: 48
Sources:
Other AEs: Eye disorders NEC, Bradycardia...
Other AEs:
Eye disorders NEC (6 patients)
Bradycardia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
0.5 % 2 times / day steady, ophthalmic
Recommended
Dose: 0.5 %, 2 times / day
Route: ophthalmic
Route: steady
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, 1 - 6 years
n = 48
Health Status: unhealthy
Condition: pediatric glaucomas
Age Group: 1 - 6 years
Sex: M+F
Population Size: 48
Sources:
Eye disorders NEC 6 patients
0.5 % 2 times / day steady, ophthalmic
Recommended
Dose: 0.5 %, 2 times / day
Route: ophthalmic
Route: steady
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, 1 - 6 years
n = 48
Health Status: unhealthy
Condition: pediatric glaucomas
Age Group: 1 - 6 years
Sex: M+F
Population Size: 48
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Levobetaxolol (Betaxon): in vitro pharmacology, intraocular pressure lowering activity and autoradiographic localization of beta-adrenoceptors in human eyes.
2001
Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.
2001 Aug
Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors.
2004 Apr
Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma.
2004 Feb 15
Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.
2007 Jun
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial.
2008 Jun
Patents

Sample Use Guides

The recommended dose is one drop of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to BETAXONTM Ophthalmic Suspension may require a few weeks to stabilize.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:03:00 UTC 2021
Edited
by admin
on Sat Jun 26 07:03:00 UTC 2021
Record UNII
75O9XHA4TU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOBETAXOLOL
INN  
INN  
Official Name English
BETAXOLOL, (S)-
Common Name English
LEVOBETAXOLOL [INN]
Common Name English
LEVOBETAXOLOL [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29576
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
Code System Code Type Description
RXCUI
353497
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL1201274
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
IUPHAR
8035
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
NCI_THESAURUS
C66006
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
EPA CompTox
93221-48-8
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
DRUG BANK
DB09351
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
PUBCHEM
60657
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
EVMPD
SUB08462MIG
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
FDA UNII
75O9XHA4TU
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
CAS
93221-48-8
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
DRUG CENTRAL
4752
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
INN
6447
Created by admin on Sat Jun 26 07:03:00 UTC 2021 , Edited by admin on Sat Jun 26 07:03:00 UTC 2021
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY